In a 26‑year‑old woman with ADHD treated with dextroamphetamine (10 mg as needed) and lisdexamfetamine (20 mg daily), also on isotretinoin and escitalopram, who has new‑onset elevated blood pressure, nightly sweats, mild proteinuria/microalbuminuria, low free thyroxine with normal thyroid‑stimulating hormone and otherwise normal labs, what is the most likely cause of her hypertension and what is the next step in management?

Most Likely Cause: Amphetamine-Induced Hypertension

The elevated blood pressure in this 26-year-old woman is most likely caused by her amphetamine medications (dextroamphetamine 10 mg PRN and lisdexamfetamine 20 mg daily), and the immediate next step is to discontinue or reduce the dose of these stimulants. 1

Rationale for Amphetamine-Induced Hypertension

Primary Evidence from Guidelines

• The 2017 ACC/AHA Hypertension Guidelines explicitly identify amphetamines (including both dextroamphetamine and lisdexamfetamine) as medications that cause elevated blood pressure. 1

• The recommended management strategy is to "discontinue or decrease dose" and "consider behavioral therapies for ADHD" as alternatives. 1

• CNS stimulants cause a mean increase in blood pressure of 2-4 mmHg systolic and diastolic, with some patients experiencing larger increases. 2

Supporting Research Evidence

• A 2025 Cochrane review of 56 RCTs (10,583 participants) found that amphetamines increased systolic blood pressure by 1.93 mmHg and diastolic blood pressure by 1.84 mmHg, with high-certainty evidence. 3

• These blood pressure increases persist with chronic use—subgroup analysis of studies ≥8 weeks showed similar sustained effects. 3

• In adults with ADHD specifically, amphetamines increased systolic blood pressure by 5.4 mmHg (p<0.05) compared to baseline. 4

• Lisdexamfetamine (the patient's daily medication) increased systolic blood pressure with an effect size of SMD -1.06 in pediatric studies, and similar effects are expected in adults. 5

FDA Drug Label Warnings

• The FDA label for lisdexamfetamine explicitly warns: "CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Some patients may have larger increases." 2

• The label mandates: "Monitor all lisdexamfetamine dimesylate capsules-treated patients for potential tachycardia and hypertension." 2

Why Other Causes Are Less Likely

Isotretinoin

• While isotretinoin can rarely affect lipids and has been associated with pseudotumor cerebri, it is not a recognized cause of sustained hypertension. 1

Escitalopram

• SSRIs like escitalopram are actually recommended as alternatives to other antidepressants (MAOIs, SNRIs, TCAs) specifically because they have fewer blood pressure effects. 1

Thyroid Dysfunction

• The low free T4 (0.81) with normal TSH (1.19) suggests possible subclinical hypothyroidism or euthyroid sick syndrome, but hypothyroidism typically causes low blood pressure, not hypertension. 1

Proteinuria/Microalbuminuria

• The albumin-creatinine ratio of 116 mg/g and +1 protein on urinalysis indicate microalbuminuria, but this is more likely a consequence of hypertension rather than the cause, particularly given the temporal relationship with stimulant use. 1

Secondary Hypertension Screening Indications

• The 2020 ISH Guidelines recommend screening for secondary hypertension in patients with early-onset hypertension (<30 years), but only "in particular in the absence of hypertension risk factors." 1
• This patient HAS a clear hypertension risk factor: amphetamine use. 1

Immediate Management Algorithm

Step 1: Address Amphetamine Medications (First Priority)

Discontinue or significantly reduce amphetamine doses immediately. 1

• Consider behavioral therapies for ADHD as alternatives. 1
• If ADHD treatment must continue, consider switching to non-stimulant options such as atomoxetine, viloxazine ER, guanfacine ER, or clonidine ER. 6, 7

Step 2: Confirm Blood Pressure Elevation

• Obtain home blood pressure monitoring (HBPM) or 24-hour ambulatory blood pressure monitoring (ABPM) to confirm sustained hypertension and exclude white coat effect. 1
• The 2020 ISH Guidelines emphasize excluding pseudoresistance, including white coat effect, before pursuing extensive workup. 1

Step 3: Evaluate for Target Organ Damage

Given the proteinuria and elevated blood pressure, assess for hypertension-mediated organ damage:

• Repeat urinalysis and albumin-creatinine ratio after discontinuing amphetamines to determine if proteinuria resolves. 1
• Calculate estimated GFR using the MDRD or Cockroft-Gault formula (comprehensive metabolic panel was normal, suggesting preserved renal function). 1
• Obtain electrocardiogram to screen for left ventricular hypertrophy. 1
• Consider echocardiography if more sensitive detection of cardiac changes is needed. 1

Step 4: Address Thyroid Abnormality

• Repeat thyroid function tests (free T4 and TSH) to clarify whether true hypothyroidism is present.
• If confirmed, initiate thyroid replacement therapy, as untreated hypothyroidism can contribute to other metabolic abnormalities.

Step 5: Reassess Blood Pressure After Stimulant Discontinuation

• Recheck blood pressure 2-4 weeks after discontinuing or reducing amphetamines. 1
• If blood pressure normalizes, this confirms drug-induced hypertension and no further workup is needed. 1
• If blood pressure remains elevated despite stimulant discontinuation, proceed to secondary hypertension evaluation. 1

Step 6: Secondary Hypertension Workup (Only if BP Remains Elevated)

If hypertension persists after amphetamine discontinuation, screen for secondary causes:

• Primary aldosteronism: Plasma aldosterone-to-renin ratio (given young age and persistent hypertension). 1
• Renal parenchymal disease: Already partially evaluated with urinalysis and creatinine; consider renal ultrasound. 1
• Renovascular hypertension: Consider if clinical suspicion is high (abdominal bruit, flash pulmonary edema, asymmetric kidneys). 1
• Obstructive sleep apnea: Assess for snoring, witnessed apneas, daytime somnolence (patient reports no snoring, making this less likely). 1

Night Sweats Consideration

• The patient reports "always" having night sweats, which is nonspecific but could suggest:

  • Amphetamine side effects (sympathetic activation). 2
  • Hyperthyroidism (ruled out by normal TSH).
  • Pheochromocytoma (rare; would expect paroxysmal hypertension, headaches, palpitations).
  • Lymphoma or other malignancy (no other constitutional symptoms mentioned).

• If night sweats persist after amphetamine discontinuation, consider further evaluation including complete blood count (already normal), inflammatory markers, and chest imaging if clinically indicated.

Common Pitfalls to Avoid

• Do not initiate antihypertensive medications before discontinuing the causative agent (amphetamines). 1
• Do not pursue extensive secondary hypertension workup before addressing drug-induced causes. 1
• Do not assume proteinuria indicates primary renal disease without first controlling blood pressure and reassessing. 1
• Do not overlook the cumulative effect of multiple amphetamine formulations (this patient is on both dextroamphetamine PRN and daily lisdexamfetamine). 1

Cardiovascular Risk Context

• Amphetamines increase the risk of withdrawals due to adverse effects (RR 2.69,95% CI 2.13-3.40), with an absolute risk increase of 4.3%. 3
• However, a large cohort study of 150,359 adults found no increased risk of serious cardiovascular events (MI, SCD, stroke) with ADHD medication use (adjusted RR 1.03,95% CI 0.86-1.24). 8
• The blood pressure increases, while statistically significant and clinically relevant for some individuals, do not appear to translate into increased acute cardiovascular events in most patients. 8

The key is that this patient is experiencing a measurable blood pressure increase that warrants intervention, regardless of long-term cardiovascular event risk.